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ABSTRAK
Tujuan: untuk membandingkan efektivitas metformin dan pioglitazon dalam memperbaiki resistensi insulin 
dan faktor risiko kardiovaskular pada wanita dengan sindroma ovarium polikistik (SOP). Metode: penelitian ini 
merupakan uji klinik acak untuk membandingkan terapi metformin dengan pioglitazon. Lima puluh dua wanita 
dengan SOP berusia 20-45 tahun dialokasi secara acak ke dalam dua kelompok perlakuan. Seluruh pasien 
menjalani pemeriksaan klinis dan biokimiawi serta pemeriksaan gula darah puasa (GDP), profil lipid dan indeks 
masa tubuh (IMT), serta kadar insulin serum sebelum dan sesudah perlakuan data dianalisis dengan MANOVA 
repeated measure. Hasil: berat badan dan IMT secara bermakna menurun pada kelompok metformin, tetapi tidak 
pada kelompok pioglitazon. GDP, kadar trigliserida serum dan kolesterol total menurun secara bermakna, baik 
pada kelompok metformin maupun kelompok pioglitazon. Resistensi insulin diukur dengan metode homeostasis 
model assessment (HOMA) dan secara bermakna menurun pada kedua kelompok perlakuan (P<0,05). Tidak ada 
perbedaan bermakna pada sebagian besar variabel, kecuali IMT. Kesimpulan: hasil penelitian ini menunjukkan 
bahwa pioglitazon sama efektifnya dengan metformin dalam memperbaiki sensitivitas insulin dan biomarker 
risiko kardiovaskular, tetapi tidak menimbulkan efek yang bermakna pada penurunan IMT dan berat badan. 
Kata kunci: sindroma ovarium polikistik, metformin, pioglitazon, resitensi insulin, faktor risiko kardiovaskular.
ABSTRACT
Aim: to compare the effectiveness of metformin and pioglitazone in ameliorating insulin resistance and 
cardiovascular risk factors in women with polycystic ovary syndrome (PCOS). Methods: this study was a 
randomized clinical trial to compare treatment with metformin and pioglitozone. Fifty two women with PCOS 
aged 20-45 years were randomly allocated to one of the two treatment groups. All patients underwent clinical and 
biochemical evaluation and analyses involving these measures which consisted of repeated measures MANOVA 
using the pre- and post-intervention fasting blood sugar (FBS), lipid profiles, body mass index (BMI), serum 
insulin in two groups. Results: weight and BMI were significantly decreased in metformin group but not in case 
of pioglitazone. FBS, serum triglycerides, total cholesterol were all reduced significantly by both metfomin and 
pioglitazone. Insulin resistance measured by homeostasis model assessment (HOMA) method was significantly 
decreased in both treatment groups (P<0.05). There were no significant differences between treatments in most 
of variables except BMI. Conclusion: these results suggest pioglitazone is as effective as metformin in improving 
insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and 
body weight.
Key words: polycystic ovary syndrome, metformin, pioglitazone, insulin resistance, cardiovascular risk factor.
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INTRODUCTION
Polycystic ovary syndrome (PCOS), a 
heterogeneous disorder of unclear etiology is 
a common hormonal disorder that affects an 
estimated 5%–10% of women of reproductive 
age. It is recognized as one of the most common 
endocrine/metabolic disorders of women. 
Not everyone with PCOS needs treatment. 
It depends on the symptoms to get and how 
much they bother. There are several treatments 
for each of the symptoms of PCOS; the choice 
among them depends upon the woman’s needs. 
In those women who are obese and try to lose 
some weight, drugs that decrease insulin levels 
can be effective in both obese and normal-
weight women. Increased Insulin Resistance 
(IR) is a cardinal feature of polycystic ovary 
syndrome.1,2 The associations of PCOS with 
insulin resistance, and the consequent increase 
in the risk for developing type 2 diabetes, 
cardiovascular disease, hypertension, central and 
overall obesity, and dyslipidemia characterized 
by low high density lipoprotein-cholesterol and 
high triglycerides levels3 and several important 
clinical implications, been reported in several 
studies. However, early treatment of associated 
metabolic abnormalities likely reduces risks of 
diabetes and heart disease.4 
Some research shows that metformin is 
helpful for treating polycystic ovary syndrome 
(PCOS). But there have not been many good-
quality studies. Most of the studies were quite 
small. The summary of 23 studies found there was 
not enough evidence to recommend metformin 
for PCOS. However, there are some problems 
with this summary that makes it hard to rely on 
completely.5 Metformin is a biguanide, approved 
as a hypoglycemic therapy in patients with 
type 2 diabetes mellitus. This agent improves 
insulin sensitivity by reducing hepatic glucose 
production, reducing lipolysis in the adipose 
tissue, increasing peripheral glucose uptake by 
the liver, skeletal muscle and adipose tissue and 
inhibiting intestinal glucose absorption.6-10 
 Pioglitazone is an orally administered 
insulin-sensitizing thiazolidinedione agent 
developed for the treatment of type 2 diabetes 
mellitus. Pioglitazone activates nuclear PPAR-g, 
which leads to the increased transcription of 
genes encoding various proteins regulating 
glucose and lipid metabolism. These proteins 
amplify the post-receptor actions of insulin in 
the liver and peripheral tissues, resulting in an 
improved glycemic control with no increase 
in endogeneous secretion of insulin.11 Both 
metformin and thiazolidinediones (TZD) are 
widely used by primary care physicians and 
specialists to treat the clinical and biochemical 
features of PCOS. However, there is no evidence-
based data supporting this indication.5,12
The aim of this study was to compare the 
effectiveness of pioglitazone and metformin 
in improving insulin sensitivity and some of 
biochemical markers and cardiovascular risk 
factors in women with PCOS.
METHODS
Participants
The study was conducted in Qazvin, Iran, 
a city near Tehran with a population of about 
500,000 at the time of study. We invited 
consecutive eligible women with PCOS who had 
come to the Endocrinology & Metabolism clinic 
of Boo’ali Hospital, Qazvin University of Medical 
Sciences from April, 2008 to August, 2009 
to receive treatment metformin (500mg three 
times a day) or pioglitazone (30mg once a day) 
regimens. At first, participants in this study were 
54 women with PCOS (M age = 25.28 years, SD 
= 4.38 years). For inclusion in the study, patients 
needed to: (a) desire to participate in this survey, 
(b) Polycystic ovary syndrome was diagnosed by 
the ESHRE/ASRM Rotterdam criteria based on 
two of three following abnormalities: Evidence 
of anovulation or oligo-ovulation, Evidence of 
clinical (hirsutism, acne, male pattern balding) 
or biochemical hyperandrogenism (high serum 
androgen concentration) and polycystic ovaries 
(confirmed by ultrasound). None of the women 
were on any medications that would alter their 
insulin resistance and none had been taking oral 
contraceptives, anti androgens or drugs to control 
their appetite at the time of enrollment or in the 
preceding 6 months. The presence of type 1 
and type 2 diabetes mellitus, thyroid disorders, 
congenital adrenal hyperplasia, persistent 
hyperprolactinemia, pituitary insufficiency 
and unsuspected pregnancy was excluded by 
laboratory tests. Criteria for exclusion during 
the study included diagnosis of pregnancy and 
increased concentration of serum transaminases 
and if they had a plan to travel in the near future 
that precluded their attendance. All participants 
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Recruitment (n=54)
Randomization (n=52)
2 refusals
26 intervention at
baseline for
metformin
26 intervention at
baseline for
pioglitazon
26 followed at
12 weeks
26 followed at
12 weeks
Figure 1. The trial profile and the proportion of women who 
completed follow-up
Table 1. Compare of characteristics and some parameters 
of non- participants and participants
N Mean ±SD t P value
Age completes 52 25.28 4.38 0.09 0.93
Non 
completes
2 25 2.12
Weight completes 52 65.77 7.22 -0.62 0.54
Non 
completes
2 69 5.66
Height completes 52 158.95 2.92 -0.27 0.79
Non 
completes
2 159.5 2.12
FBS completes 52 93.84 11.81 -0.32 0.75
Non 
completes
2 96.5 2.12
TG completes 52 170.86 47.67 -0.5 0.62
Non 
completes
2 188 16.97
CHOL completes 52 160.07 35.83 -1.11 0.28
Non 
completes
2 188 33.94
HDL completes 52 40.93 5.46 0.11 0.91
Non 
completes
2 40.5 3.54
Insulin completes 52 16.7 8.61 -1.2 0.24
Non 
completes
2 24.2 8.2
BMI completes 52 26.03 2.7 -0.55 0.58
Non 
completes
2 27.1 1.5
LDL completes 52 84.97 30.35 -1.14 0.26
Non 
completes
2 109.9 27.01
Note: BMI: Body Mass Index, TG: Triglyceride, LDL: 
Low Density Lipoprotein, CHOL: cholesterol, HDL: High 
Density Lipoprotein, FBS: Fasting Blood Sugar
provided written informed consent before 
enrolment and responses were confidential. The 
ethics review board of the Qazvin University of 
Medical Science approved the study. We randomly 
allocated the patients to two intervention groups 
using 14 blocks A, B (AABB, ABAB, etc.) 
of Balanced Blocked Randomization method. 
Before the randomization, two patients did not 
follow the study because of various reasons. 
Flow chart of study and the proportion of women 
who completed follow-up have been shown in 
Figure 1. 
Patient non-completers were similar to 
completers for age and the other parameters. 
(Table 1).
Measures
Measures  were completed pr ior  to 
commencing the group program and 3-months 
following completion of the program. Group 
1 consisted of 26 patients, received metformin 
(500mg three times a day) and group 2 consisted 
of 26 other subjects, received pioglitozone (30mg 
once daily). The patients’ treatment codes were 
kept until the end of the trial by a third party. 
Since the drugs had different daily dose schedules 
(i.e., three times a day for metformin and once 
a day for pioglitazone), the study had an open 
design. After initiation of the study, the subjects 
were advised not to alter their dietary habits or 
modify their physical exercise patterns. After 
preliminary clinical and laboratory studies, all 
subjects began a 3-month period of treatment. 
During the study, monthly outpatient visits 
performed to evaluate the side effects of the 
drugs and enhance patient compliance and rate 
of follow-up. At each follow-up visit, menstrual 
status was recorded including the dates of last 
menstrual periods and the regularity of menses 
was assessed (in the 3-month block). 
Procedures
At study entry, all patients underwent clinical 
and biochemical evaluations that included weight, 
BMI, FBS, Triglycerides, Total Cholesterol, 
LDL- cholesterol, HDL- cholesterol and serum 
insulin level. At baseline, serum insulin level 
was assayed using ELISA direct method (EIA) 
supplied by Monoband Kits, USA. FBS, TG, 
Chol, LDL and HDL were measured using a 
Hitachi analyzer (Tokyo, Japan). The Insulin 
resistance was calculated using the homeostasis 
model assessment (HOMA) method (HOMA-
IR= [insulin*glucose] /22.5). At the end of 
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Table 2. Compare of participants’ parameters in two 
Intervention Group (metformin, pioglitazone) at base line
Name N Mean ±SD t p value
Age metformin 26 25.32 4.31 0.08 0.94
pioglitazone 26 25.23 4.52
Weight metformin 26 66.07 7.8 0.31 0.76
pioglitazone 26 65.46 6.73
Height metformin 26 158.96 3.26 0.05 0.96
pioglitazone 26 158.93 2.6
FBS metformin 26 95.12 12.34 0.53 0.6
pioglitazone 26 92.73 11.88
TG metformin 26 171.08 52.06 -0.28 0.78
pioglitazone 26 171.46 45.57
CHOL metformin 26 159.96 39.2 -0.28 0.78
pioglitazone 26 159.39 33.63
HDL metformin 26 40.96 6.08 0.29 0.77
pioglitazone 26 40.73 5.14
Insulin metformin 26 17.09 9.86 0.27 0.79
pioglitazone 26 15.88 7.59
BMI metformin 26 26.13 3.03 0.31 0.76
pioglitazone 26 25.82 2.61
LDL metformin 26 84.79 32.9 -0.3 0.77
pioglitazone 26 84.36 28.91
Index metformin 26 75.62 50.11 0.35 0.72
HOMA pioglitazone 26 68.43 41.98
Note: HOMA-IR: Homeostasis Model Assessment 
Index for Insulin Resistance, BMI: Body Mass Index, 
TG: Triglyceride, LDL: Low Density Lipoprotein, CHOL: 
cholesterol, HDL: High Density Lipoprotein, FBS: 
Fasting Blood Sugar
third month, the same clinical and biochemical 
assessments were performed by the same staff 
and the same kits. 
Statistical Analysis
Analyses involving these measures consisted 
of Repeated Measures MANOVA using the 
pre- and post-intervention FBS, lipid profiles, 
Insulin, BMI in two groups. Analyses were 
performed separately for patients for each of the 
two independent variables.
RESULTS
Sample Equivalence
Fifty two subjects completed the study (26 in 
each study group). We first assessed distribution 
of variables before using parametric analyses 
and results showed that all of them were normal. 
So we compared the biochemical characteristics 
of the two groups. Using t-tests, there was no 
significant difference between them (Table 2) 
on any of the variables.
Intervention Effects
First, we conducted Repeated measures 
MANOVA; there were not main effects for 
treatment in the most variables except BMI 
(Table 3). Means and standard deviations for all 
biochemical characteristics of metformin at pre- 
and post-intervention compared to the pioglitazon 
are shown.
Effect sizes were large: d =1.41 on BMI for 
metformin and small: d=0.02 for pioglitazon. 
In addition, effect sizes on insulin were large: d 
=1.59 and 1.58 for pioglitazon and metformin 
respectively. We were also interested in clinical 
significance and we used a 50-percentile 
distribution of changes BMI and Insulin 
from baseline to post-assessment as clinical 
significance. Of the 26 patients who received the 
metformin, 2.65% decrease on BMI and 35.31% 
on Insulin had been showed. Of the 26 patients 
who received pioglitazone, 0% decrease on BMI 
and 33.68% on Insulin had been showed. 
The baseline HOMA index was statistically 
comparable between the two groups. After 
3 months of treatment, HOMA index was 
significantly decreased in both groups (p<0.05) 
and this decrement was not statistically different 
between the two groups. After treatment period, 
FBS and lipid profile decreased significantly 
in the two treatment groups but there were no 
statistical difference between the two groups. 
DISCUSSION
Metformin therapy has been shown to 
have beneficial effects on Insulin Resistance in 
nondiabetic women with PCOS and its use in 
women with PCOS is now regarded as acceptable 
practice.1,13-15 Pioglitazone has also been shown 
to improve the metabolic outcomes of PCOS.1,14 
This study was conducted to assess the metabolic 
changes and variability of insulin resistance 
(as representative of cardiovascular risk profile 
modification) happened following treatment with 
medications in women with PCOS.
Our  s tudy  showed  tha t  3 -mon ths 
administration of pioglitazone in women 
with PCOS was as effective as metformin in 
improving Insulin resistance and cardiovascular 
risk profile but not in reduction of weight and 
BMI as components of metabolic syndrome. 
Pioglitazone and metformin caused similar 
significant decreases in FBS, TG, total cholesterol 
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Table 3. Repeated measures MANOVA in two Intervention Group (metformin, pioglitazone) after 3 months follow up
Treatment Mean ± SD N Time*treatment f p value
FBS Pre metformin 95.12 12.34 26 0.49 0.49
pioglitazone 92.73 11.88 26
Post metformin 86.92 8.46 26
pioglitazone 85.69 6.49 26
TG Pre metformin 171.08 52.06 26 0.006 0.94
pioglitazone 171.46 45.57 26
Post metformin 151.04 43.83 26
pioglitazone 151.04 38.21 26
CHOL Pre metformin 159.96 39.2 26 0.22 0.64
pioglitazone 159.39 33.63 26
Post metformin 147.62 36.38 26
pioglitazone 148.12 29.06 26
HDL Pre metformin 40.96 6.08 26 3.49 0.07
pioglitazone 40.73 5.14 26
Post metformin 44.15 4.64 26
pioglitazone 42.42 4.24 26
LDL Pre metformin 84.79 32.9 26 1.37 0.25
pioglitazone 84.36 28.91 26
Post metformin 73.25 30.08 26
pioglitazone 75.49 24 26
BMI Pre metformin 26.13 3.03 26 32.16 0.001
pioglitazone 25.82 2.61 26
Post metformin 25.51 2.81 26
pioglitazone 25.83 2.55 26
Insulin Pre metformin 17.09 9.86 26 0.06 0.81
pioglitazone 15.88 7.59 26
Post metformin 11.10 6.32 26
pioglitazone 10.15 4.84 26
Index Pre Metformin 75.62 50.11 26 0.13 0.72
HOMA pioglitazone 68.43 41.98 26
Post metformin 44.29 27.68 26
pioglitazone 39.54 21.52 26
Note: HOMA-IR: Homeostasis Model Assessment Index for Insulin Resistance, BMI: Body Mass Index, TG: Triglyceride, 
LDL: Low Density Lipoprotein, CHOL: cholesterol, HDL: High Density Lipoprotein, FBS: Fasting Blood Sugar
and LDL-cholesterol and comparable significant 
increase in HDL-cholesterol.
The study showed that weight reduction with 
pioglitazone was not comparable to metformin, 
however, reduction in Insulin Resistance 
(HOMA-IR) was comparable in both treatment 
groups. Regarding to the role of insulin resistance 
that had at least one component of metabolic 
syndrome in cardiovascular risk of patients, this 
decrease can be potentially beneficial in such 
patients.16
In this study, the drug selected from 
thiazolidinedione group was pioglitazone which 
had the least adverse effects in comparison with 
the others and its use as once daily regimen made 
it a better choice compared with metformin. One 
study showed the use of pioglitazone during 
12 weeks resulting in a significant decrease 
in glycated hemoglobin, fasting glycemia, 
and postprandial reduction in insulinemia and 
insulin resistance index HOMA-IR, as well as 
an improvement of lipid blood spectrum and the 
lessening of visceral obesity. Besides, a positive 
effect on arterial pressure was noted. The study 
revealed no significant adverse effects; good 
tolerance to treatment was noted in 90% of the 
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patients.17 Some data suggest that amelioration of 
clinical and biochemical parameters provoked by 
these targeted metabolic interventions in women 
with PCOS could be jeopardized by an increase 
in bodyweight and BMI.18 However, in our head- 
to-head study, both drugs had no adverse effects 
on Body Mass Index and moreover, metformin 
had significant beneficial effect on this component 
of metabolic syndrome. Another study showed 
that Pioglitazone has an important therapeutic 
pathway in diabetes mellitus and cardiovascular 
diseases, even in metabolic syndrome. 19 women 
with PCOS may demonstrate higher inter- and 
intra- individual variation in the IR-HOMA index 
than control women without PCOS.20,21 It has 
been proposed that, at any level of IR, a decline 
by more than 31% is needed in a subsequent 
sample to ascribe any change to a therapeutic 
intervention.20,21 These decrements demonstrate 
that amelioration of insulin resistance in our 
subjects due to metformin and pioglitazone 
trial has clinically significant outcomes. This 
statement would have direct implications in our 
day to day practice regarding PCOS patients. 
In this study, we had limitations to follow up 
the patients more than 3months, Further studies 
with longer follow-up period can provide a better 
understanding of the effectiveness of the drugs.
CONCLUSION
In summary, our parallel trial demonstrated 
that administration of pioglitazone and metformin 
for 3 months had similar effects in improving 
insulin resistance in women with PCOS. 
Metformin, but not pioglitazone, caused a 
significant decrease in body weight and BMI. Both 
drugs have beneficial effects on cardiovascular 
risk profile in as short durations as 3 months and 
can potentially reduce coronary cardiac risk in 
women with PCOS.
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